Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. News
  7. Summary
    SAN   FR0000120578

SANOFI

(SAN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sanofi Lifts 2021 Guidance After 2Q Sales Grew

07/29/2021 | 01:51am EDT

By Cecilia Butini

Sanofi SA said Thursday that sales grew in the second quarter and raised its full-year guidance.

The French pharmaceutical major posted a declining net profit for the quarter compared with the same period in 2020, when the metric went up as a result of a share repurchase transaction completed with Regeneron Pharmaceuticals Inc.

Net profit came in at 1.21 billion euros ($1.43 billion) for the period, from EUR7.60 billion in the same period the year prior, on sales that grew to EUR8.74 billion from EUR8.21 billion in the same quarter of 2020.

Business net income --a key profit metric that excludes some items-- increased to EUR1.73 billion from EUR1.60 billion the year prior.

Business earnings per share were EUR1.38 in the quarter, up from EUR1.28 in 2020.

The company revised its outlook upwards, now guiding for 2021 business EPS growth of around 12% at constant exchange rates, barring unforeseen adverse events. Sanofi had previously guided for business EPS growth in the high-single digits at constant exchange rates.

Write to Cecilia Butini at cecilia.butini@wsj.com

(END) Dow Jones Newswires

07-29-21 0150ET

All news about SANOFI
09/27SANOFI : SVB Leerink Upgrades Sanofi to Outperform from Market Perform
MT
09/27SANOFI : - Availability of the Q3 2021 Memorandum for modelling purposes
AQ
09/27SANOFI : New research presented at IDWeek 2021 reinforces Sanofi's robust vaccines pipelin..
PU
09/27Global vaccines project to revamp rules after Britain got more than Botswana
RE
09/24SANOFI : Availability of the Q3 2021 Memorandum for modelling purposes
AQ
09/23SANOFI : New Dupixent« (dupilumab) data in patients as young as 6 years old with moderate-..
PU
09/23VC DAILY : Biotechs Seek New Skill Set From -2-
DJ
09/23SANOFI : Deutsche Bank keeps a Sell rating
MD
09/22PRESS RELEASE : Pfizer and BioNTech Expand -3-
DJ
09/21SANOFI : New Dupixent« (dupilumab) data in patients as young as 6 years old with moderate-..
AQ
More news
Analyst Recommendations on SANOFI
More recommendations
Financials
Sales 2021 37 292 M 43 601 M 43 601 M
Net income 2021 6 046 M 7 069 M 7 069 M
Net Debt 2021 7 878 M 9 211 M 9 211 M
P/E ratio 2021 17,2x
Yield 2021 4,01%
Capitalization 103 B 121 B 121 B
EV / Sales 2021 2,98x
EV / Sales 2022 2,72x
Nbr of Employees 99 412
Free-Float 88,4%
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | MarketScreener
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 82,12 €
Average target price 104,78 €
Spread / Average Target 27,6%
EPS Revisions
Managers and Directors
Paul Hudson Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Serge Weinberg Chairman
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capi. (M$)
SANOFI4.35%120 616
JOHNSON & JOHNSON3.68%432 675
ROCHE HOLDING AG10.16%321 605
PFIZER, INC.19.37%246 358
NOVO NORDISK A/S50.45%231 485
ELI LILLY AND COMPANY34.09%210 037